Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

2025-521828-30-00 Protocol PYX-201-102 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 27 Jan 2026 · Status Ongoing, recruiting · 3 EU/EEA countries · 11 sites · Protocol PYX-201-102

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 100
Countries 3
Sites 11

Advanced Solid Tumors

Key facts

Sponsor
Pyxis Oncology Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Jan 2026 → ongoing
Decision date (initial)
2025-11-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-521828-30-00
ClinicalTrials.gov
NCT06795412

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pyxis Oncology Inc.

Sponsor organisation
Pyxis Oncology Inc.
Address
321 Harrison Avenue
City
Boston
Postcode
02118-2659
Country
United States

Scientific contact point

Organisation
Pyxis Oncology Inc.
Contact name
Clinical Trial Manager

Public contact point

Organisation
Pyxis Oncology Inc.
Contact name
Clinical Trial Manager

Locations

3 EU/EEA countries · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 9 5
Poland Ended 2 1
Spain Ongoing, recruiting 10 5
Rest of world
United States
79

Investigational sites

France

5 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Bordeaux
Medical Oncology, 1 Rue Jean Burguet, 33000, Bordeaux
Institut Bergonie
Medical Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Hospitalier Regional De Marseille
Centre d’Essais Précoces en Cancérologie de Marseille (CEPCM), 264 Rue Saint Pierre, 13005, Marseille
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
Medical Oncologist, 114 Rue Edouard Vaillant, 94800, Villejuif

Poland

1 site · Ended
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Oddział w Gliwicach; Centrum Wsparcia Badań Klinicznych, Ul. Wybrzeze Armii Krajowej 15, 44-102, Gliwice

Spain

5 sites · Ongoing, recruiting
Hospital Universitario 12 De Octubre
Oncology department, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitari Vall D Hebron
Oncology department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Ramon Y Cajal
Oncology department, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Clinico Universitario De Valencia
Oncology department, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Fundacion Jimenez Diaz
Oncology department, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2026-02-19 2026-05-04
Spain 2026-01-27 2026-04-09

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-30 Spain Acceptable
2025-11-18
2025-11-19
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-11 Spain Acceptable
2025-11-18
2025-12-11
3 SUBSTANTIAL MODIFICATION SM-1 2026-02-05 Spain Acceptable
2026-04-17
2026-04-17